{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:04:28Z","timestamp":1784243068323,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>No data exist for the long-term outcome of metastatic colorectal cancer (mCRC) from the Southern part of Asia. The primary objective of the study is to evaluate the survival outcome of mCRC from an Indian tertiary care center. The study also aims to highlight the treatment pattern practiced and the unique clinico-pathologic characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a single-center retrospective observational study done at a large referral tertiary care center in North India. All patients with synchronous or metachronous mCRC who received at least one dose of chemotherapy for metastatic disease, registered between 2003 to 2017 were included. Primary outcome measures were overall survival and progression-free survival and prognostic factors of overall survival. Descriptive analysis was done for the clinicopathological characteristics and treatment patterns. Kaplan Meier method for overall survival and progression-free survival. Cox regression analysis was performed for the determination of the prognostic factors for overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>Out of 377 eligible patients, 256 patients (68%) had de novo metastatic disease and the remaining 121 (32%) progressed to metastatic disease after initial treatment. The cohort was young (median age, 46\u2009years) with the most common primary site being the rectum. A higher proportion of signet (9%) and mucinous histology (24%). The three common sites of metastasis were the liver, peritoneum, and lung. In the first line, most patients received oxaliplatin-based chemotherapy (70%). Only 12.5% of patients received biologicals in the first-line setting. The median follow-up and median overall survival of study cohort were 17\u2009months and 18.5\u2009months. The factors associated with poor outcome for overall survival on multivariate analysis were ECOG performance status of &gt;\u20091, high CEA, low albumin, and the number of lines of chemotherapy received (&lt;\u20092).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The outcome of mCRC is inferior to the published literature. We found a relatively higher proportion of patients with the following characteristics; younger, rectum as primary tumor location, the signet, and mucinous histology, higher incidence of peritoneum involvement. The routine use of targeted therapies is limited. Government schemes (inclusion of targeted therapies in the Ayushman scheme), NGO assistance, and availability of generic low-cost targeted drugs may increase the availability.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-021-08398-z","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T20:06:35Z","timestamp":1622232395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center"],"prefix":"10.1186","volume":"21","author":[{"given":"Vinod","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Raina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Dabkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bidhu Kalyan","family":"Mohanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. K.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushmita","family":"Pathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Thulkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. V. S.","family":"Deo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"8398_CR1","unstructured":"IACR - GLOBOCAN [Internet]. [cited 2020 May 15]. Available from: http:\/\/www.iacr.com.fr\/index.php?option=com_content&view=article&id=101&Itemid=578"},{"issue":"11","key":"8398_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1470-2045(05)70422-8","volume":"6","author":"JJ Sung","year":"2005","unstructured":"Sung JJ, Lau JY, Goh K, Leung W. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6(11):871\u20136. https:\/\/doi.org\/10.1016\/S1470-2045(05)70422-8.","journal-title":"Lancet Oncol"},{"issue":"10","key":"8398_CR3","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1136\/gutjnl-2019-320271","volume":"69","author":"A Mathew","year":"2020","unstructured":"Mathew A, Baby B, Wang K, Sirohi B, Lei F, Chen Q, et al. Colorectal cancer incidence in younger adults in India. Gut. 2020;69(10):1899\u2013900. https:\/\/doi.org\/10.1136\/gutjnl-2019-320271.","journal-title":"Gut."},{"issue":"1","key":"8398_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdx738","volume":"29","author":"T Yoshino","year":"2018","unstructured":"Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu R-H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(1):44\u201370.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"12","key":"8398_CR5","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1200\/JOP.2016.018382","volume":"12","author":"A Mahipal","year":"2016","unstructured":"Mahipal A, Grothey A. Role of biologics in first-line treatment of colorectal Cancer. J Oncol Pract. 2016;12(12):1219\u201328. https:\/\/doi.org\/10.1200\/JOP.2016.018382.","journal-title":"J Oncol Pract"},{"key":"8398_CR6","unstructured":"NCRP Anual Reports... [Internet]. [cited 2020 May 15]. Available from: http:\/\/ncdirindia.org\/NCRP\/Annual_Reports.aspx"},{"issue":"2","key":"8398_CR7","first-page":"83","volume":"22","author":"SV Deo","year":"2001","unstructured":"Deo SV, Shukla NK, Srinivas G, Mohanti BK, Raina V, Sharma A, et al. Colorectal cancers--experience at a regional cancer Centre in India. Trop Gastroenterol Off J Dig Dis Found. 2001;22(2):83\u20136.","journal-title":"Trop Gastroenterol Off J Dig Dis Found"},{"issue":"3","key":"8398_CR8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4103\/0019-509X.12680","volume":"41","author":"S Deo","year":"2004","unstructured":"Deo S, Kumar S, Shukla NK, Kar M, Mohanti BK, Sharma A, et al. Patient profile and treatment outcome of rectal cancer patients treated with multimodality therapy at a regional cancer center. Indian J Cancer. 2004;41(3):120\u20134.","journal-title":"Indian J Cancer"},{"issue":"4","key":"8398_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s13193-017-0655-0","volume":"8","author":"PS Patil","year":"2017","unstructured":"Patil PS, Saklani A, Gambhire P, Mehta S, Engineer R, De\u2019Souza A, et al. Colorectal Cancer in India: an audit from a tertiary Center in a low Prevalence Area. Indian J Surg Oncol. 2017;8(4):484\u201390. https:\/\/doi.org\/10.1007\/s13193-017-0655-0.","journal-title":"Indian J Surg Oncol."},{"issue":"10","key":"8398_CR10","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/bjs.10573","volume":"104","author":"MR Thompson","year":"2017","unstructured":"Thompson MR, O\u2019Leary DP, Flashman K, Asiimwe A, Ellis BG, Senapati A. Clinical assessment to determine the risk of bowel cancer using symptoms, age, mass and Iron deficiency anaemia (SAMI). Br J Surg. 2017;104(10):1393\u2013404. https:\/\/doi.org\/10.1002\/bjs.10573.","journal-title":"Br J Surg"},{"key":"8398_CR11","unstructured":"Census of India Website: Office of the Registrar General & Census Commissioner, India [Internet]. [cited 2020 May 15]. Available from: https:\/\/censusindia.gov.in\/"},{"issue":"10","key":"8398_CR12","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1111\/j.1572-0241.1999.01454.x","volume":"94","author":"SR Majumdar","year":"1999","unstructured":"Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol. 1999;94(10):3039\u201345. https:\/\/doi.org\/10.1111\/j.1572-0241.1999.01454.x.","journal-title":"Am J Gastroenterol"},{"key":"8398_CR13","unstructured":"Cancer Research UK [Internet]. [cited 2020 May 15]. Available from: https:\/\/www.cancerresearchuk.org\/"},{"issue":"6","key":"8398_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s12664-009-0087-z","volume":"28","author":"MC Peedikayil","year":"2009","unstructured":"Peedikayil MC, Nair P, Seena SM, Radhakrishnan L, Sadasivan S, Naryanan VA, et al. Colorectal cancer distribution in 220 Indian patients undergoing colonoscopy. Indian J Gastroenterol Off J Indian Soc Gastroenterol. 2009;28(6):212\u20135. https:\/\/doi.org\/10.1007\/s12664-009-0087-z.","journal-title":"Indian J Gastroenterol Off J Indian Soc Gastroenterol"},{"issue":"3","key":"8398_CR15","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/annonc\/mdt591","volume":"25","author":"N Hugen","year":"2014","unstructured":"Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(3):651\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdt591.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"issue":"2","key":"8398_CR16","first-page":"122","volume":"32","author":"A Mukherji","year":"2011","unstructured":"Mukherji A, Rathi AK, Sharma K, Kumar V, Singh K, Bahadur AK. A study on presentation and behavior of Colo-rectal carcinoma in young Indian patients. Trop Gastroenterol Off J Dig Dis Found. 2011;32(2):122\u20137.","journal-title":"Trop Gastroenterol Off J Dig Dis Found."},{"issue":"11","key":"8398_CR17","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"J-Y Douillard","year":"2013","unstructured":"Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab\u2013FOLFOX4 treatment and RAS mutations in colorectal Cancer. N Engl J Med. 2013;369(11):1023\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1305275.","journal-title":"N Engl J Med"},{"issue":"15","key":"8398_CR18","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"S Tejpar","year":"2011","unstructured":"Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and Leucovorin as first-line treatment for metastatic colorectal Cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8398_CR19","doi-asserted-by":"publisher","first-page":"101042831769226","DOI":"10.1177\/1010428317692265","volume":"39","author":"M Jauhri","year":"2017","unstructured":"Jauhri M, Bhatnagar A, Gupta S, BP M, Minhas S, Shokeen Y, et al. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: next-generation sequencing\u2013based cohort study. Tumor Biol. 2017;39(2):1010428317692265. https:\/\/doi.org\/10.1177\/1010428317692265.","journal-title":"Tumor Biol"},{"issue":"9","key":"8398_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s12032-014-0124-3","volume":"31","author":"S Bisht","year":"2014","unstructured":"Bisht S, Ahmad F, Sawaimoon S, Bhatia S, Das BR. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. Med Oncol. 2014;31(9):124. https:\/\/doi.org\/10.1007\/s12032-014-0124-3.","journal-title":"Med Oncol"},{"issue":"9","key":"8398_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2217\/bmm-2016-0358","volume":"11","author":"G Kafatos","year":"2017","unstructured":"Kafatos G, Niepel D, Lowe K, Jenkins-Anderson S, Westhead H, Garawin T, et al. RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data. Biomark Med. 2017;11(9):751\u201360. https:\/\/doi.org\/10.2217\/bmm-2016-0358.","journal-title":"Biomark Med"},{"issue":"2","key":"8398_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andr\u00e9 T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal Cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229\u201337. https:\/\/doi.org\/10.1200\/JCO.2004.05.113.","journal-title":"J Clin Oncol"},{"issue":"22","key":"8398_CR23","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1200\/JCO.2005.07.113","volume":"23","author":"G Colucci","year":"2005","unstructured":"Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal Cancer: a multicenter study of the Gruppo Oncologico Dell\u2019Italia Meridionale. J Clin Oncol. 2005;23(22):4866\u201375. https:\/\/doi.org\/10.1200\/JCO.2005.07.113.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8398_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","volume":"18","author":"S Giacchetti","year":"2000","unstructured":"Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(1):136\u201347. https:\/\/doi.org\/10.1200\/JCO.2000.18.1.136.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"8398_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jso.20196","volume":"89","author":"S Stelzner","year":"2005","unstructured":"Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol. 2005;89(4):211\u20137. https:\/\/doi.org\/10.1002\/jso.20196.","journal-title":"J Surg Oncol"},{"issue":"9","key":"8398_CR26","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1634\/theoncologist.2011-0039","volume":"16","author":"B Chibaudel","year":"2011","unstructured":"Chibaudel B, Bonnetain F, Tournigand C, Bengrine-Lefevre L, Teixeira L, Artru P, et al. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist. 2011;16(9):1228\u201338. https:\/\/doi.org\/10.1634\/theoncologist.2011-0039.","journal-title":"Oncologist"},{"issue":"2","key":"8398_CR27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/annonc\/mdf034","volume":"13","author":"CH K\u00f6hne","year":"2002","unstructured":"K\u00f6hne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol Off J Eur Soc Med Oncol. 2002;13(2):308\u201317. https:\/\/doi.org\/10.1093\/annonc\/mdf034.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"4","key":"8398_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3816\/CCC.2003.n.004","volume":"2","author":"AL Yuste","year":"2003","unstructured":"Yuste AL, Aparicio J, Segura A, L\u00f3pez-Tendero P, Giron\u00e9s R, P\u00e9rez-Fidalgo JA, et al. Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal Cancer treated with 5-fluorouracil\u2014based chemotherapy. Clin Colorectal Cancer. 2003;2(4):231\u20134. https:\/\/doi.org\/10.3816\/CCC.2003.n.004.","journal-title":"Clin Colorectal Cancer"},{"issue":"8","key":"8398_CR29","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/cas.12451","volume":"105","author":"GW Prager","year":"2014","unstructured":"Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, et al. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci. 2014;105(8):996\u20131001. https:\/\/doi.org\/10.1111\/cas.12451.","journal-title":"Cancer Sci"},{"issue":"1","key":"8398_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1634\/theoncologist.12-1-38","volume":"12","author":"RM Goldberg","year":"2007","unstructured":"Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB, et al. The continuum of care: a paradigm for the Management of Metastatic Colorectal Cancer. Oncologist. 2007;12(1):38\u201350. https:\/\/doi.org\/10.1634\/theoncologist.12-1-38.","journal-title":"Oncologist"},{"issue":"36","key":"8398_CR31","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1200\/JCO.2005.04.4792","volume":"23","author":"A Grothey","year":"2005","unstructured":"Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(36):9441\u20132. https:\/\/doi.org\/10.1200\/JCO.2005.04.4792.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"8398_CR32","doi-asserted-by":"publisher","unstructured":"Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in\u00a0patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392. https:\/\/doi.org\/10.1001\/jama.2017.7105.","DOI":"10.1001\/jama.2017.7105"},{"issue":"2","key":"8398_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","volume":"3","author":"S Tejpar","year":"2017","unstructured":"Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal Cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194\u2013201. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3797.","journal-title":"JAMA Oncol"},{"key":"8398_CR34","doi-asserted-by":"publisher","unstructured":"Fountzilas G, Gossios K, Zisiadis A, Svarna E, Skarlos D, Pavlidis N. Prognostic variables in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. Med Pediatr Oncol. 1996;26(5):305\u201317. https:\/\/doi.org\/10.1002\/(SICI)1096-911X(199605)26:5<305::AID-MPO2>3.0.CO;2-M.","DOI":"10.1002\/(SICI)1096-911X(199605)26:5<305::AID-MPO2>3.0.CO;2-M"},{"issue":"7","key":"8398_CR35","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/annonc\/mdh267","volume":"15","author":"E Mitry","year":"2004","unstructured":"Mitry E, Douillard J-Y, Van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol. 2004;15(7):1013\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdh267.","journal-title":"Ann Oncol"},{"issue":"16","key":"8398_CR36","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(16):2938\u201347. https:\/\/doi.org\/10.1200\/JCO.2000.18.16.2938.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"15","key":"8398_CR37","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1200\/JCO.2011.38.0915","volume":"30","author":"KM Tveit","year":"2012","unstructured":"Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of Cetuximab with continuous or intermittent fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal Cancer: the NORDIC-VII study. J Clin Oncol. 2012;30(15):1755\u201362. https:\/\/doi.org\/10.1200\/JCO.2011.38.0915.","journal-title":"J Clin Oncol"},{"issue":"41","key":"8398_CR38","doi-asserted-by":"publisher","first-page":"15049","DOI":"10.3748\/wjg.v20.i41.15049","volume":"20","author":"C De Divitiis","year":"2014","unstructured":"De Divitiis C. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality. World J Gastroenterol. 2014;20(41):15049\u201359. https:\/\/doi.org\/10.3748\/wjg.v20.i41.15049.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"8398_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41571-020-00445-1","volume":"18","author":"N Akimoto","year":"2021","unstructured":"Akimoto N, Ugai T, Zhong R, Hamada T, Fujiyoshi K, Giannakis M, et al. Rising incidence of early-onset colorectal cancer \u2014 a call to action. Nat Rev Clin Oncol. 2021;18(4):230\u201343. https:\/\/doi.org\/10.1038\/s41571-020-00445-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"8398_CR40","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1136\/gutjnl-2019-319511","volume":"68","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Torre LA, Soerjomataram I, Hayes RB, Bray F, Weber TK, et al. Global patterns and trends in colorectal cancer incidence in young adults. Gut. 2019;68(12):2179\u201385. https:\/\/doi.org\/10.1136\/gutjnl-2019-319511.","journal-title":"Gut."},{"issue":"6","key":"8398_CR41","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41575-019-0253-4","volume":"17","author":"LJ Hofseth","year":"2020","unstructured":"Hofseth LJ, Hebert JR, Chanda A, Chen H, Love BL, Pena MM, et al. Early-onset colorectal cancer: initial clues and current views. Nat Rev Gastroenterol Hepatol. 2020;17(6):352\u201364. https:\/\/doi.org\/10.1038\/s41575-019-0253-4.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"8398_CR42","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s13193-017-0670-1","volume":"8","author":"AB Pokharkar","year":"2017","unstructured":"Pokharkar AB, Bhandare M, Patil P, Mehta S, Engineer R, Saklani AP. Young vs old colorectal Cancer in Indian subcontinent: a tertiary care center experience. Indian J Surg Oncol. 2017;8(4):491\u20138. https:\/\/doi.org\/10.1007\/s13193-017-0670-1.","journal-title":"Indian J Surg Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08398-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08398-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08398-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T08:36:13Z","timestamp":1699086973000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08398-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8398"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08398-z","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was taken from institute ethical committee (AIIMS, All India Institute of Medical Sciences, New Delhi). Informed consent was exempted by the ethical committee (AIIMS, All India Institute of Medical Sciences, New Delhi).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"630"}}